Skip to content 
FDA OTC Drug Regulations — Monograph System, Cosmetic-Drug Products & Compliance
Many personal care products — including sunscreens, anti-acne treatments, anti-dandruff shampoos, and skin protectants — are regulated as Over-the-Counter (OTC) drugs by the FDA, not as cosmetics. Understanding the difference is essential for market access and compliance. Cosmereg helps brands navigate OTC drug requirements including establishment registration, product listing, labeling, and GMP.
✅ OTC drug establishment registration
✅ Drug listing & NDC assignment
✅ Drug Facts labeling compliance
✅ Monograph & NDA pathway guidance
✅ GMP compliance (21 CFR 210/211)
✅ Cosmetic-drug dual classification support
What Is an OTC Drug?
Over-the-Counter (OTC) drugs are medications that can be sold directly to consumers without a prescription. The FDA regulates OTC drugs under the Federal Food, Drug, and Cosmetic Act (FD&C Act) to ensure they are safe and effective for their intended use when used according to label directions.
Unlike cosmetics, which are intended only to cleanse, beautify, or alter appearance, OTC drugs make therapeutic claims — such as treating symptoms, preventing disease, or affecting the structure or function of the body. Products like sunscreens, acne treatments, anti-dandruff shampoos, antiperspirants, and fluoride toothpastes all fall under FDA OTC drug regulations.
Key distinction: If a product makes any claim to treat, prevent, cure, or mitigate a disease or condition, the FDA considers it a drug — regardless of how it is marketed or perceived by consumers. Products that serve both cosmetic and therapeutic functions are regulated as both a cosmetic and a drug simultaneously.
Two Pathways to Market OTC Drugs in the U.S.
The FDA provides two distinct regulatory pathways for marketing OTC drugs. The pathway a company follows depends on the product's active ingredients and intended use.
OTC Drug Monograph System
The monograph pathway allows OTC drugs to be marketed without individual FDA pre-approval — as long as the product complies with an applicable monograph. A monograph is a set of conditions (active ingredients, dosages, labeling, indications, and testing requirements) under which an OTC drug category is deemed Generally Recognized as Safe and Effective (GRASE).
The CARES Act of 2020 modernized this system, replacing the old rulemaking process with a faster administrative order process under Section 505G of the FD&C Act. Monographs cover therapeutic categories such as sunscreen, antacids, analgesics, cough/cold, anti-dandruff, and more.
New Drug Application (NDA)
Products that do not fit within an existing OTC monograph — including those with new active ingredients, new combinations, or novel indications — require an approved New Drug Application (NDA) before marketing.
The NDA pathway requires clinical trial data demonstrating safety and efficacy, and involves a thorough FDA review process. Some products initially approved as prescription drugs can later be “switched” to OTC status through an NDA supplement (Rx-to-OTC switch).
Cosmetic, Drug, or Both? Understanding Dual Classification
One of the most common compliance pitfalls is misclassifying a product. The FDA determines classification based on intended use — evaluated through marketing claims, consumer expectations, product ingredients, and labeling. Many personal care products fall into a "cosmetic-drug" dual classification, meaning they must comply with both cosmetic regulations (including MoCRA) and OTC drug regulations simultaneously.
| Product | Classification | Why? |
|---|---|---|
| Moisturizer | Cosmetic | Beautifies/alters appearance only |
| SPF Moisturizer / Sunscreen | Cosmetic + Drug | SPF claim = prevents sunburn (therapeutic) |
| Anti-acne Cleanser | Cosmetic + Drug | Treats acne (salicylic acid, benzoyl peroxide) |
| Anti-dandruff Shampoo | Cosmetic + Drug | Active ingredient treats dandruff condition |
| Antiperspirant | Drug | Affects body function (reduces perspiration) |
| Fluoride Toothpaste | Cosmetic + Drug | Prevents cavities (therapeutic claim) |
| Skin Protectant / Diaper Cream | Drug | Protects against irritation (therapeutic) |
| Regular Lipstick | Cosmetic | Alters appearance only |
| Medicated Lip Balm (SPF or menthol) | Cosmetic + Drug | Therapeutic active ingredient present |
Why this matters: Products classified as drugs — even partially — must comply with drug establishment registration (21 CFR Part 207), drug listing with NDC numbers, Drug Facts labeling format, GMP under 21 CFR Parts 210 and 211, and adverse event reporting. Cosmereg helps brands determine their correct regulatory classification and navigate dual-classification compliance.
OTC Drug Compliance Requirements
Whether your product follows the monograph pathway or the NDA pathway, the following federal requirements apply to all OTC drugs marketed in the United States.
Drug Establishment Registration
Every domestic and foreign facility that manufactures, repackages, relabels, or salvages OTC drug products must register with the FDA under 21 CFR Part 207. Registration is submitted electronically through the FDA’s Drug Registration and Listing System (DRLS). Foreign establishments must designate a U.S. Agent. Registration must be renewed annually between October 1 and December 31.
Drug Product Listing
Each OTC drug product must be listed with the FDA, including its active and inactive ingredients, dosage form, route of administration, and National Drug Code (NDC). Listings must be submitted in Structured Product Labeling (SPL) format and updated when formulations or labeling change.
Drug Facts Labeling
All OTC drugs must display a standardized “Drug Facts” panel on their labeling, as required under 21 CFR 201.66. This panel must include the active ingredient(s) and purpose, uses (indications), warnings, directions, and inactive ingredients — presented in a specific format and order. Products with dual cosmetic-drug classification must include both the Drug Facts panel and standard cosmetic ingredient labeling.
Good Manufacturing Practices (GMP)
OTC drugs must be manufactured in compliance with Current Good Manufacturing Practice (cGMP) regulations under 21 CFR Parts 210 and 211. These cover facility design, equipment maintenance, quality control, laboratory testing, production records, and personnel qualifications. FDA inspects drug manufacturing facilities to verify cGMP compliance.
Adverse Event Reporting
Manufacturers, packers, and distributors of OTC drugs are required to report serious adverse events to the FDA. For OTC drugs, this falls under the Dietary Supplement and Nonprescription Drug Consumer Protection Act, which requires reporting within 15 business days of receiving a serious adverse event report.
OTC Monograph User Fees (OMUFA)
Under the Over-the-Counter Monograph Drug User Fee Amendments (OMUFA), facilities that manufacture OTC monograph drugs are subject to annual user fees. OMUFA was reauthorized through FY 2030, and the FDA publishes updated fee rates annually. Companies should budget for both facility fees and any applicable OTC Monograph Order Request (OMOR) fees.
Our OTC Drug Compliance Services
Cosmereg provides end-to-end regulatory support for OTC drug products and cosmetic-drug products entering the U.S. market.
Product Classification
We evaluate your product claims, ingredients, and intended use to determine whether your product is a cosmetic, OTC drug, or both — and advise on the correct regulatory pathway.
Establishment Registration
We handle FDA drug establishment registration through DRLS, including U.S. Agent designation for foreign facilities and annual renewal management.
Drug Product Listing
We prepare and submit drug product listings in SPL format, including NDC assignment, ingredient disclosure, and monograph category coding.
Drug Facts Labeling
We review and design compliant Drug Facts panels, verify active/inactive ingredient declarations, and ensure dual-label compliance for cosmetic-drug products.
GMP & Quality Support
We provide gap analysis and consulting for cGMP compliance under 21 CFR 210/211, helping facilities prepare for FDA inspections.
Monograph Compliance
We verify that your OTC drug formulation, labeling, and indications conform to the applicable FDA monograph conditions for your therapeutic category.
Frequently Asked Questions About FDA OTC Drug Regulations
Cosmetics are intended to cleanse, beautify, or alter appearance. OTC drugs are intended to treat, prevent, or cure a disease or condition, or to affect the structure or function of the body. The classification is based on the product's intended use, which is determined by claims, ingredients, and consumer expectations. Products that do both — like SPF moisturizers — are regulated as both a cosmetic and a drug.
A monograph is an FDA-established set of conditions — including approved active ingredients, dosages, indications, warnings, and labeling — under which an OTC drug category is considered Generally Recognized as Safe and Effective (GRASE). Products that comply with an applicable monograph can be marketed without individual FDA pre-approval or an NDA.
It depends on the pathway. OTC monograph drugs can be marketed without FDA pre-approval as long as they comply with all conditions in the applicable monograph. Products that use new active ingredients or don't fit within an existing monograph require an approved New Drug Application (NDA) before marketing.
Yes. Sunscreens are regulated as OTC drugs in the United States (under Monograph M020). This means the manufacturing facility must be registered as a drug establishment, the product must be listed with an NDC number, Drug Facts labeling is required, and manufacturing must comply with cGMP under 21 CFR 210/211.
The CARES Act of 2020 modernized the OTC drug monograph system by replacing the slow rulemaking process with a faster administrative order process. It also introduced the OMUFA user fee program, which requires OTC monograph drug facilities to pay annual fees to support FDA oversight activities. These changes are ongoing, with OMUFA reauthorized through FY 2030.
OTC drugs must comply with Current Good Manufacturing Practice (cGMP) regulations under 21 CFR Parts 210 and 211. These are more prescriptive than cosmetic GMP standards and cover facility design, equipment, quality control, testing, production records, and personnel training. FDA inspects drug facilities to verify compliance.
Dual-classified products must comply with both sets of regulations simultaneously. This means meeting cosmetic requirements (MoCRA facility registration, product listing, cosmetic labeling) AND drug requirements (drug establishment registration, drug product listing, Drug Facts label, cGMP under 21 CFR 210/211, and adverse event reporting).
Yes. Cosmereg provides drug establishment registration, product listing, and U.S. Agent designation for foreign facilities manufacturing OTC drugs for the U.S. market. We handle both the drug registration (via DRLS) and cosmetic registration (via Cosmetics Direct) for dual-classified products.
Need Help with OTC Drug Compliance?
Whether you're launching a sunscreen, anti-acne product, or any cosmetic-drug product in the U.S. market, Cosmereg provides the expertise to get you compliant.
